RESUMEN
The unbound concentrations of 14 commercial drugs, including five non-efflux/uptake transporter substrates-Class I, five efflux transporter substrates-class II and four influx transporter substrates-Class III, were simultaneously measured in rat liver, muscle, and blood via microanalysis. Kpuu,liver and Kpuu,muscle were calculated to evaluate the membrane transport activity and cell metabolism on the unbound drug concentrations in the skeletal muscle and liver. For Class I compounds, represented by antipyrine, unbound concentrations among liver, muscle and blood are symmetrically distributed when compound hepatic clearance is low. And when compound hepatic clearance is high, unbound concentrations among liver, muscle and blood are asymmetrically distributed, such as Propranolol. For Class II and III compounds, overall, the unbound concentrations among liver, muscle, and blood are asymmetrically distributed due to a combination of hepatic metabolism and efflux and/or influx transporter activity.
Asunto(s)
Membrana Celular/metabolismo , Hígado/metabolismo , Proteínas de Transporte de Membrana/metabolismo , Músculo Esquelético/metabolismo , Preparaciones Farmacéuticas/metabolismo , Animales , Antipirina/sangre , Antipirina/metabolismo , Atenolol/sangre , Atenolol/metabolismo , Carbamazepina/sangre , Carbamazepina/metabolismo , Digoxina/sangre , Digoxina/metabolismo , Diltiazem/sangre , Diltiazem/metabolismo , Difenhidramina/sangre , Difenhidramina/metabolismo , Vías de Eliminación de Fármacos , Gabapentina/sangre , Gabapentina/metabolismo , Lamotrigina/sangre , Lamotrigina/metabolismo , Memantina/sangre , Memantina/metabolismo , Microdiálisis , Ofloxacino/sangre , Ofloxacino/metabolismo , Preparaciones Farmacéuticas/sangre , Propranolol/sangre , Propranolol/metabolismo , Pirilamina/sangre , Pirilamina/metabolismo , Quinidina/sangre , Quinidina/metabolismo , Ratas , Terfenadina/análogos & derivados , Terfenadina/sangre , Terfenadina/metabolismoRESUMEN
BACKGROUND: Although psychostimulants apparently do cross the BBB, it is poorly understood how these hydrophilic and positively charged molecules can pass the blood-brain barrier (BBB). That may be mediated by a genetically still uncharacterized H+/OC antiporter with high activity at the BBB. METHODS: We studied the uptake of 16 psychostimulants and hallucinogens with hCMEC/D3 cells using the prototypic inhibitor imipramine (cis-inhibition), exchange transport with diphenhydramine and clonidine (trans-stimulation), proton dependency of the uptake, and we characterized the concentration-dependent uptake. RESULTS: Cell uptake of methylenedioxyamphetamines, amphetamines and dimethyltryptamine (DMT) were strongly inhibited (to about 10% of the controls) by imipramine and diphenhydramine, whereas uptake of cathine was only weakly inhibited and mescaline not significantly. Amphetamine, methylamphetamine, para-Methoxy-N-methylamphetamine (PMMA), Methylenedioxymethamphetamine (MDMA), phentermine and DMT exhibited the highest exchange after preloading with diphenhydramine with only 5.5%, 5.2%, 7.8%, 6%, 1.9%, 7.6% remaining in the cells. Less and no exchange were seen with cathine and mescaline, respectively. Dependence on intracellular pH was most pronounced with the methylendioxyamphetamines while uptake of cathine, DOI and cocaine were only moderately affected and mescaline not at all. CONCLUSION: Except for mescaline, all psychostimulants studied here were substrates of the H+/OC antiporter, implicating a strong need for a better characterization of this transport protein.
Asunto(s)
Antiportadores/metabolismo , Barrera Hematoencefálica/metabolismo , Encéfalo/metabolismo , Estimulantes del Sistema Nervioso Central/metabolismo , Proteínas de Transporte de Catión Orgánico/metabolismo , Antiportadores/antagonistas & inhibidores , Barrera Hematoencefálica/efectos de los fármacos , Encéfalo/efectos de los fármacos , Células Cultivadas , Estimulantes del Sistema Nervioso Central/farmacología , Difenhidramina/metabolismo , Difenhidramina/farmacología , Relación Dosis-Respuesta a Droga , Humanos , Imipramina/metabolismo , Imipramina/farmacología , Proteínas de Transporte de Catión Orgánico/antagonistas & inhibidores , Bombas de Protones/metabolismoRESUMEN
Brain penetration of cationic drugs is an important determinant of their efficacy and side effects. However, the effects of alterations in the activity of uptake transporters in the brain under inflammatory conditions on the brain penetration of cationic drugs are not fully understood. The aim of this study was to examine changes in brain penetration of cationic drugs, including diphenhydramine (DPHM), memantine (MMT), and cimetidine (CMD), and changes in the expression of uptake transporters such as organic cation transporter (Oct) in brain microvascular endothelial cells (BMECs) under inflammatory conditions. To clarify the effects of inflammation on the brain penetration of DPHM, MMT, and CMD, we performed brain microdialysis studies in a rat model of adjuvant-induced arthritis (AA). Further, differences in transporter mRNA expression levels between BMECs from control and AA rats were evaluated. Brain microdialysis showed that the unbound brain-to-plasma partition coefficient (Kp,uu,brain) for DPHM and MMT was significantly lower in AA rats compared with control rats. OCT mRNA levels were increased and proton-coupled organic cation (H+/OC) antiporter mRNA levels were decreased in AA rats compared with control rats. Taken together, our findings suggest that inflammation decreases the brain penetration of H+/OC antiporter substrates such as DPHM and MMT.
Asunto(s)
Encéfalo/metabolismo , Difenhidramina/farmacología , Memantina/farmacología , Animales , Antiportadores/genética , Antiportadores/metabolismo , Antiportadores/farmacología , Artritis/tratamiento farmacológico , Transporte Biológico/genética , Barrera Hematoencefálica/metabolismo , Encéfalo/efectos de los fármacos , Cimetidina/farmacología , Difenhidramina/metabolismo , Células Endoteliales/metabolismo , Femenino , Inflamación/tratamiento farmacológico , Inflamación/fisiopatología , Memantina/metabolismo , Microdiálisis/métodos , Ratas , Ratas Sprague-DawleyRESUMEN
Cisplatin is widely used as an anti-tumor drug for the treatment of solid tumors. Unfortunately, it causes kidney toxicity as a critical side effect, limiting its use, given that no preventive drug against cisplatin-induced kidney toxicity is currently available. Here, based on a repositioning analysis of the Food and Drug Administration Adverse Events Reporting System, we found that a previously developed drug, diphenhydramine, may provide a novel treatment for cisplatin-induced kidney toxicity. To confirm this, the actual efficacy of diphenhydramine was evaluated in in vitro and in vivo experiments. Diphenhydramine inhibited cisplatin-induced cell death in kidney proximal tubular cells. Mice administered cisplatin developed kidney injury with significant dysfunction (mean plasma creatinine: 0.43 vs 0.15 mg/dl) and showed augmented oxidative stress, increased apoptosis, elevated inflammatory cytokines, and MAPKs activation. However, most of these symptoms were suppressed by treatment with diphenhydramine. Furthermore, the concentration of cisplatin in the kidney was significantly attenuated in diphenhydramine-treated mice (mean platinum content: 70.0 vs 53.4 µg/g dry kidney weight). Importantly, diphenhydramine did not influence or interfere with the anti-tumor effect of cisplatin in any of the in vitro or in vivo experiments. In a selected cohort of 98 1:1 matched patients from a retrospective database of 1467 patients showed that patients with malignant cancer who had used diphenhydramine before cisplatin treatment exhibited significantly less acute kidney injury compared to ones who did not (6.1 % vs 22.4 %, respectively). Thus, diphenhydramine demonstrated efficacy as a novel preventive medicine against cisplatin-induced kidney toxicity.
Asunto(s)
Lesión Renal Aguda , Antineoplásicos , Lesión Renal Aguda/inducido químicamente , Lesión Renal Aguda/tratamiento farmacológico , Lesión Renal Aguda/prevención & control , Animales , Antineoplásicos/toxicidad , Apoptosis , Cisplatino/toxicidad , Difenhidramina/metabolismo , Difenhidramina/farmacología , Difenhidramina/uso terapéutico , Humanos , Riñón/metabolismo , Ratones , Estrés Oxidativo , Estudios RetrospectivosRESUMEN
Estuaries routinely receive discharges of contaminants of emerging concern from urban regions. Within these dynamic estuarine systems, salinity and pH can vary across spatial and temporal scales. Our previous research identified bioaccumulation of the calcium channel blocker diltiazem and the antihistamine diphenhydramine in several species of fish residing in multiple urban estuaries along the Gulf of Mexico in Texas, where field-measured observations of diltiazem in fish plasma exceeded human therapeutic plasma doses. However, there remains a limited understanding of pharmaceutical bioaccumulation in estuarine environments. Here, we examined the influence of pH and salinity on bioconcentration of three pharmaceuticals in the Gulf killifish, Fundulus grandis. F. grandis were exposed to low levels of the ionizable pharmaceuticals carbamazepine, diltiazem, and diphenhydramine at two salinities (5â¯ppt, 20â¯ppt) and two pH levels (6.7, 8.3). pH influenced bioconcentration of select weak base pharmaceuticals, while salinity did not, suggesting that intestinal uptake via drinking does not appear to be a major exposure route of these pharmaceuticals in killifish. Compared to our previous pH dependent uptake observations with diphenhydramine in the fathead minnow model, killifish apparent volume of distribution values were markedly lower than fatheads, though killifish bioconcentration factors were similar at high pH and four fold higher at low pH than freshwater fish. Advancing an understanding of environmental gradient influences on pharmacokinetics among fish is necessary to improve bioaccumulation assessments and interpretation of toxicological observations for ionizable contaminants.
Asunto(s)
Estuarios , Fundulidae/metabolismo , Concentración de Iones de Hidrógeno , Preparaciones Farmacéuticas/metabolismo , Salinidad , Animales , Carbamazepina/metabolismo , Diltiazem/metabolismo , Difenhidramina/metabolismo , Golfo de México , Humanos , Farmacocinética , Texas , Contaminantes Químicos del Agua/análisis , Contaminantes Químicos del Agua/metabolismoRESUMEN
While emerging pharmaceutical contaminants are monitored in wastewater treatment and the environment, there is little information concerning their microbial metabolites. The transformation of diphenhydramine by microorganisms in anaerobic digester sludge was investigated using anaerobic cultures amended with 1â¯mM diphenhydramine as the sole carbon source. Complete transformation of the parent compound to a persistent metabolite occurred within 191 days. Using GC/MS analysis, the metabolite was identified as N-desmethyl diphenhydramine. Loss of the parent compound diphenhydramine followed a first order rate constant of 0.013 day-1. There was no observed decrease in metabolite concentration even after a further 12 months of incubation, suggesting that the metabolite resists further degradation during wastewater treatment. Bacterial community diversity in the diphenhydramine transforming assay cultures showed enrichment in Comamonadaceae, Symbiobacteriaceae, Anaerolineaceae, and Prevotellaceae relative to unamended background controls. An anaerobic toxicity assay demonstrated that diphenhydramine has an inhibitory effect on both fermentative bacteria and methanogenic archaea in the wastewater community. In contrast, the metabolite N-desmethyl diphenhydramine partially suppressed methanogens but did not impact the fermenting community. To our knowledge, this is the first report of diphenhydramine metabolism by a bacterial community. The limited transformation of diphenhydramine by wastewater microorganisms indicates that N-desmethyl diphenhydramine will enter the environment along with unmetabolized diphenhydramine.
Asunto(s)
Difenhidramina/metabolismo , Aguas Residuales/microbiología , Anaerobiosis , Bacterias/metabolismo , Desmetilación , Antagonistas de los Receptores Histamínicos/metabolismo , Aguas del Alcantarillado/microbiologíaRESUMEN
The aim of present study is to formulate diphenhydramine nasal nano-emulgels, having lipophilic nano-sized interior droplets, with better penetration for targeted controlled delivery to mucous membrane. Different diphenhydramine (DPH) nasal nano-emulgels were developed having propylene glycol and olive oil (as permeation enhancers) by using RSM for optimization and then evaluated for physico-chemical characteristics and thermal stability. In-vitro drug release through cellophane membrane was conducted and results were analyzed statistically. Further, gelation, mucoadhesive stress, and ex-vivo and histopathological studies were performed on optimized formulation by using goat nasal membrane. Among all formulations, E2 showed maximum DPH release at higher concentration olive oil (4%) and lower concentration propylene glycol (PG) (25%) within 4 h. All formulations have followed first-order kinetics and drug release mechanism was Fickian diffusion. Analysis of variance (ANOVA) and multiple linear regression analysis (MLRA) were used to compare results among formulations and 3D surface plots were constructed also. Optimized formulation showed immediate prolong gelation in artificial nasal mucosa and excellent mucoadhesive property (72.5 ± 1.5 dynes/cm2). Approximately 97.1% optimized formulation was permeated through membrane within 4 h, having a high flux rate (33.19 ± 0.897 µg/cm2/min) with diffusion coefficient (0.000786 ± 4.56 × 10-5 cm2/min) while drug contents remained on mucosal membrane for 24 h. Histopathologically, change on intra-mucosal surface of excised membrane was observed due to passage of drug through it. In summary, combination of PG and olive oil in nasal DPH nano-emulgel can be utilized successfully for targeted controlled delivery. The optimized formulation has excellent permeability and prolonged residence time on mucosal surface, which prove its good anti-histaminic activity in case of allergic rhinitis.
Asunto(s)
Difenhidramina/administración & dosificación , Difenhidramina/metabolismo , Mucosa Nasal/efectos de los fármacos , Mucosa Nasal/metabolismo , Animales , Difenhidramina/química , Composición de Medicamentos , Sistemas de Liberación de Medicamentos/métodos , Evaluación Preclínica de Medicamentos/métodos , Liberación de Fármacos , Geles , Cabras , Antagonistas de los Receptores Histamínicos H1/administración & dosificación , Antagonistas de los Receptores Histamínicos H1/química , Antagonistas de los Receptores Histamínicos H1/metabolismo , Humanos , Aceite de Oliva/administración & dosificación , Aceite de Oliva/química , Aceite de Oliva/metabolismo , Permeabilidad , Propilenglicol/administración & dosificación , Propilenglicol/química , Propilenglicol/metabolismoRESUMEN
Varenicline is a selective partial α4ß2 nicotinic acetylcholine receptor agonist, which is used to help achieve smoking cessation. Here, we investigated varenicline transport at the blood-brain barrier by means of in vivo microdialysis, in situ brain perfusion, and brain efflux index measurements in rats, and in vitro uptake studies in human brain capillary endothelial cells. Microdialysis demonstrated that varenicline is actively transported from blood to brain in rats. Blood-to-brain uptake transport of varenicline, as measured by the in situ brain perfusion technique, was strongly inhibited by diphenhydramine, a potent inhibitor of proton-coupled organic cation (H+/OC) antiporter. However, brain efflux index study showed that brain-to-blood efflux transport of varenicline was not inhibited by diphenhydramine. In human brain capillary endothelial cells, varenicline was taken up time- and concentration-dependently. The uptake was dependent on an oppositely directed proton gradient, but was independent of extracellular sodium and membrane potential. The uptake was inhibited by a metabolic inhibitor, and by substrates of H+/OC antiporter, but not by substrates or inhibitors of OCTs, OCTNs, PMAT, and MATE1, which are known organic cation transporters. The present results suggest that the H+/OC antiporter contributes predominantly to varenicline uptake at the blood-brain barrier.
Asunto(s)
Antiportadores/metabolismo , Barrera Hematoencefálica/metabolismo , Células Endoteliales/metabolismo , Agonistas Nicotínicos/metabolismo , Receptores Nicotínicos/metabolismo , Vareniclina/metabolismo , Animales , Antiportadores/química , Transporte Biológico , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Difenhidramina/química , Difenhidramina/metabolismo , Endotelio Vascular/metabolismo , Humanos , Cinética , Masculino , Agonistas Nicotínicos/administración & dosificación , Agonistas Nicotínicos/química , Proteínas de Transporte de Catión Orgánico/metabolismo , Protones , Ratas , Termodinámica , Vareniclina/administración & dosificación , Vareniclina/químicaRESUMEN
Though bioaccumulation of pharmaceuticals has received attention in inland waters, studies of pharmaceutical bioaccumulation in estuarine and marine systems are limited. Further, an understanding of pharmaceutical bioaccumulation across size classes of organisms displaying ontogenetic feeding shifts is lacking. We selected the striped mullet, Mugil cephalus, a euryhaline and eurythermal species that experiences dietary shifts with age, to identify whether a model base, diphenhydramine, accumulated in a tidally influenced urban bayou. We further determined whether diphenhydramine accumulation differed among size classes of striped mullet over a two year study period. Stable isotope analysis identified that ontogenetic feeding shifts of M. cephalus occurred from juveniles to adults. However, bioaccumulation of diphenhydramine did not significantly increase across age classes of M. cephalus but corresponded to surface water levels of the pharmaceutical, which suggests inhalational uptake to diphenhydramine was more important for bioaccumulation than dietary exposure in this urban estuary.
Asunto(s)
Difenhidramina/metabolismo , Monitoreo del Ambiente , Estuarios , Smegmamorpha/metabolismo , Contaminantes Químicos del Agua/metabolismo , Animales , DietaRESUMEN
Multiwalled carbon nanotubes (MWCNTs) and pharmaceutical compounds are classified by the US Environmental Protection Agency as contaminants of emerging concern, with significant research devoted to determining their potential environmental and toxicological effects. Multiwalled carbon nanotubes are known to have a high adsorptive capacity for organic contaminants, leading to potential uses in water remediation; however, there is concern that co-exposure with MWCNTs may alter the bioavailability of organic compounds. Existing studies investigating MWCNT/organic contaminant co-exposures have shown conflicting results, and no study to date has examined the combined effects of MWCNTs and a common pharmaceutical. In the present study, juvenile fathead minnows (Pimephales promelas) were exposed to sublethal concentrations of the over-the-counter antihistamine diphenhydramine (DPH) in the presence of natural sediment for 10 d, with some treatment groups receiving MWCNTs. Addition of MWCNTs did not have a protective effect on DPH-related growth inhibition, and did not reduce the whole-body burden of DPH in exposed fish. Mass-balance calculations indicated that significant amounts of DPH were adsorbed to MWCNTs, and DPH concentrations in water and sediment were commensurately reduced. Bioconcentration factor and biota-sediment accumulation factor increased in the presence of MWCNTs, indicating that P. promelas accumulates DPH adsorbed to MWCNTs in sediment, likely by co-ingestion of MWCNTs during feeding from the sediment surface. Environ Toxicol Chem 2017;36:320-328. © 2016 SETAC.
Asunto(s)
Cyprinidae/metabolismo , Difenhidramina/toxicidad , Sedimentos Geológicos/química , Nanotubos de Carbono/química , Contaminantes Químicos del Agua/toxicidad , Adsorción , Animales , Disponibilidad Biológica , Carga Corporal (Radioterapia) , Cyprinidae/fisiología , Difenhidramina/metabolismo , Contaminantes Químicos del Agua/metabolismoRESUMEN
Motion sickness medications such as Travelmin® prescribed in Japan include diphenhydramine (DPH), dyphylline, diphenidol, and/or caffeine. Herein, we report a patient who died due to rhabdomyolysis after ingesting a DPH containing motion sickness medication. A Japanese male in his 30 s reported missing after going out for a drive early in the morning was found dead in his car in the evening of the same day. An autopsy showed moderate edema, congestion, and several petechiae in both lungs. The brain was congested and edematous with no atherosclerosis of cerebral arteries. The prostate and both testes were slightly edematous. Gastric contents included approximately 15 mL of dark-brown fluid without tablets or food residue. Toxicological examination showed that blood DPH levels in all tissues were between 4.90 and 7.27 µg/mL, which represented toxic to lethal levels. DPH (µg/mL) levels were approximately 3-9 times higher in the prostate (73.42) and testes (left, 28.23; right, 30.09) than those in all regions of the brain (range 7.75-12.33). Blood dyphylline, diphenidol and caffeine levels in reproductive organs reached high, but not toxic levels. In conclusion, DPH, dyphylline, diphenidol, and caffeine levels were higher in reproductive organs such as the prostate and testes than in the central nervous system and heart. As we determined in this case, motion sickness medications might accumulate in reproductive organs. Thus, further examination of tissue biodistribution of DPH, dyphylline, diphenidol, and caffeine is necessary to assess their potential long-term effects in these sites.
Asunto(s)
Difenhidramina/metabolismo , Sobredosis de Droga/metabolismo , Próstata/metabolismo , Testículo/metabolismo , Adulto , Autopsia , Difenhidramina/toxicidad , Sobredosis de Droga/patología , Humanos , Masculino , Próstata/patología , Testículo/patología , Distribución TisularRESUMEN
Diphenhydramine (DPH), an antihistamine used to alleviate human allergies, is widespread in aquatic environments. However, little is known about the biochemical and behavioral effects of DPH on non-target aquatic animals. In the present study, the tissue distribution, bioconcentration, metabolism, biochemical and behavioral effects were investigated in crucian carp (Carassius auratus) exposed to various concentrations of DPH (0.84, 4.23, 21.7 and 112 µg L(-1)) for 7d. DPH can accumulate in crucian carp, and high concentrations have been observed in the liver and brain with maximum bioconcentration factors of 148 and 81.6, respectively. A portion of the absorbed DPH was metabolized by the crucian carp to N-demethyl DPH and N,N-didemethyl DPH via N-demethylation. Direct fluorimetric assay was employed to assess metabolic activity, while oxidative stress and neurotransmission biomarkers were determined by Diagnostic Reagent Kits. DPH was found to increase hepatic 7-ethoxyresorufin O-deethylase activity in crucian carp with maximal induction of 119%. Concerning the oxidative stress status, DPH significantly inhibited superoxide dismutase (SOD, 37-58%) and glutathione S-transferase (GST, 43-65%) activities and led to a significant increase in malondialdehyde (MDA, 67-140%) levels and catalase (CAT, 38-143%) and glutathione peroxidase (GPx, 39-189%) activities in fish liver. Brain acetylcholinesterase activity was also induced in DPH-exposed crucian carp with maximal induction of 174%. In addition, shoaling was significantly enhanced, while swimming activity and feeding rates were markedly suppressed at DPH concentrations equal to or higher than 21.7 µg L(-1). Furthermore, significant correlations were found between oxidative stress biomarkers (SOD, CAT, GPx, GST and MDA) and behavioral parameters. Collectively, our results confirmed that DPH can accumulate and be metabolized in fish and exert a negative effect at different levels of biological organization.
Asunto(s)
Carpas/fisiología , Difenhidramina/toxicidad , Contaminantes Químicos del Agua/toxicidad , Animales , Biomarcadores/metabolismo , Catalasa/metabolismo , Citocromo P-450 CYP1A1/metabolismo , Difenhidramina/metabolismo , Glutatión Peroxidasa/metabolismo , Glutatión Transferasa/metabolismo , Estrés Oxidativo , Superóxido Dismutasa/metabolismo , Contaminantes Químicos del Agua/metabolismoRESUMEN
Biosolids contain a variety of pharmaceuticals and personal care products (PPCPs). Studies have observed the uptake of PPCPs into plants grown in biosolids-amended soils. This study examined the ability of Dynamic Plant Uptake (DPU) model and Biosolids-amended Soil Level IV (BASL4) model to predict the concentration of eight PPCPs in the tissue of plants grown in biosolids-amended soil under a number of exposure scenarios. Concentrations in edible tissue predicted by the models were compared to concentrations reported in the literature by calculating estimated human daily intake values for both sets of data and comparing them to an acceptable daily intake value. The equilibrium partitioning (EqP) portion of BASL4 overpredicted the concentrations of triclosan, triclocarban, and miconazole in root and shoot tissue by two to three orders of magnitude, while the dynamic carrot root (DCR) portion overpredicted by a single order of magnitude. DPU predicted concentrations of triclosan, triclocarban, miconazole, carbamazepine, and diphenhydramine in plant tissues that were within an order of magnitude of concentrations reported in the literature. The study also found that more empirical data are needed on the uptake of cimetidine, fluoxetine, and gemfibrozil, and other ionizable PPCPs, to confirm the utility of both models. All hazard quotient values calculated from literature data were below 1, with 95.7% of hazard quotient values being below 0.1, indicating that consumption of the chosen PPCPs in plant tissue poses de minimus risk to human health.
Asunto(s)
Cosméticos/metabolismo , Productos Agrícolas/metabolismo , Modelos Teóricos , Preparaciones Farmacéuticas/metabolismo , Aguas del Alcantarillado , Contaminantes del Suelo/metabolismo , Agricultura/métodos , Carbamazepina/metabolismo , Carbanilidas/metabolismo , Cimetidina/metabolismo , Difenhidramina/metabolismo , Fluoxetina/metabolismo , Gemfibrozilo/metabolismo , Miconazol/metabolismo , Raíces de Plantas/metabolismo , Brotes de la Planta/metabolismo , Triclosán/metabolismoRESUMEN
Previous studies showed that caffeine, diphenhydramine, and carbamazepine were bioconcentrated by mosquito fish (Gambusia holbrooki) from freshwater bodies directly affected by reclaimed water. To understand the uptake, depuration, and bioconcentration factors (BCFs) under the worst-case conditions, the authors exposed 84 mosquito fish to reclaimed water under static renewal for 7 d, followed by a 14-d depuration phase in clean water. Characterization of the exposure media revealed the presence of 26 pharmaceuticals, whereas only 5 pharmaceuticals-caffeine, diphenhydramine, diltiazem, carbamazepine, and ibuprofen-were present in the organisms after only 5 h of exposure. Caffeine, diltiazem, and carbamazepine were quickly taken up by mosquito fish following a similar uptake curve. Diphenhydramine and ibuprofen, on the other hand, were more gradually taken up by mosquito fish but were also eliminated fairly quickly, resulting in the 2 shortest depuration half-lives at 34 h and 32 h, respectively. For comparison, BCFs based on rate constants (BCFb ), steady-state concentrations (BCFa ), and saturation-state concentrations (BCFc ) were calculated. Values of BCFb ranged from 0.23 to 29 and increased in the order of caffeine < carbamazepine < diltiazem < diphenhydramine < ibuprofen. Values of BCFa and BCFc ranged from 2.0 to 28 and increased in the order of carbamazepine < caffeine < diltiazem < diphenhydramine < ibuprofen. This is the first study using a nonartificial exposure-treated wastewater matrix to generate pharmacokinetic data for pharmaceutical mixtures in aquatic organisms. Environ Toxicol Chem 2013;32:1752-1758. © 2013 SETAC.
Asunto(s)
Ciprinodontiformes/metabolismo , Preparaciones Farmacéuticas/metabolismo , Contaminantes Químicos del Agua/metabolismo , Animales , Cafeína/análisis , Cafeína/metabolismo , Carbamazepina/análisis , Carbamazepina/metabolismo , Difenhidramina/análisis , Difenhidramina/metabolismo , Agua Dulce/química , Ibuprofeno/análisis , Ibuprofeno/metabolismo , Preparaciones Farmacéuticas/análisis , Eliminación de Residuos Líquidos , Aguas Residuales/química , Contaminantes Químicos del Agua/análisisRESUMEN
Recent observations revealed that human UDP-glucuronosyltransferase (UGT) 2B10 catalyzes N-glucuronidation of amine-containing compounds. Knowledge of the substrate specificity and clinical significance of UGT2B10 is still limited. The purpose of this study was to expand the knowledge of UGT2B10 substrates and to evaluate its significance in drug clearance. Using recombinant UGT2B10, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole, and midazolam. These are drugs that were previously reported to be substrates for UGT1A4 or UGT1A3, and that contain in their structure either tertiary aliphatic amines, cyclic amines, or an imidazole group. UGT2B10 was inactive in the glucuronidation of desipramine, nortriptyline, carbamazepine, and afloqualone. This group of drugs contains secondary or primary amines, and these results suggest that UGT2B10 preferably conjugates tertiary amines. This preference is partial because UGT2B10 did not conjugate the tertiary cyclic amine in trifluoperazine. Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher. These findings suggest that UGT2B10 plays a major role in the N-glucuronidation of these drugs at therapeutic concentrations. These results are also supported by inhibition studies with nicotine and hecogenin. In conclusion, this study expands the understanding of the substrate specificity of UGT2B10, highlighting its preference for tertiary amines with higher affinities and clearance values than those of UGT1A4 and UGT1A3.
Asunto(s)
Glucurónidos/metabolismo , Glucuronosiltransferasa/fisiología , Amitriptilina/metabolismo , Animales , Difenhidramina/metabolismo , Humanos , Imipramina/metabolismo , Cinética , Spodoptera , Especificidad por SustratoRESUMEN
Nicotine, the main tobacco alkaloid leading to smoking dependence, rapidly crosses the blood-brain barrier (BBB) to become concentrated in the brain. Recently, it has been shown that nicotine interacts with some organic cation transporters (OCT), but their influence at the BBB has not yet been assessed in vivo. In this study, we characterized the transport of nicotine at the mouse luminal BBB by in situ brain perfusion. Its influx was saturable and followed the Michaelis-Menten kinetics (K(m)=2.60 mM, V(max)=37.60 nmol/s/g at pH 7.40). At its usual micromolar concentrations in the plasma, most (79%) of the net transport of nicotine at the BBB was carrier-mediated, while passive diffusion accounted for 21%. Studies on knockout mice showed that the OCT Oct1-3, P-gp, and Bcrp did not alter [(3)H]-nicotine transport at the BBB. Neither did inhibiting the transporters Mate1, Octn, or Pmat. The in vivo manipulation of intracellular and/or extracellular pH, the chemical inhibition profile, and the trans-stimulation experiments demonstrated that the nicotine transporter at the BBB shared the properties of the clonidine/proton antiporter. The molecular features of this proton-coupled antiporter have not yet been identified, but it also transports diphenhydramine and tramadol and helps nicotine cross the BBB at a faster rate and to a greater extent. The pharmacological inhibition of this nicotine/proton antiporter could represent a new strategy to reduce nicotine uptake by the brain and thus help curb addiction to smoking.
Asunto(s)
Transportadoras de Casetes de Unión a ATP/metabolismo , Antiportadores/metabolismo , Barrera Hematoencefálica/metabolismo , Nicotina/metabolismo , Proteínas de Transporte de Catión Orgánico/metabolismo , Transportadoras de Casetes de Unión a ATP/deficiencia , Transportadoras de Casetes de Unión a ATP/efectos de los fármacos , Transportadoras de Casetes de Unión a ATP/genética , Animales , Antiportadores/efectos de los fármacos , Unión Competitiva , Transporte Biológico , Barrera Hematoencefálica/efectos de los fármacos , Difusión , Difenhidramina/metabolismo , Concentración de Iones de Hidrógeno , Cinética , Masculino , Ratones , Ratones Noqueados , Modelos Biológicos , Dinámicas no Lineales , Proteínas de Transporte de Catión Orgánico/deficiencia , Proteínas de Transporte de Catión Orgánico/efectos de los fármacos , Proteínas de Transporte de Catión Orgánico/genética , Perfusión , Tramadol/metabolismoRESUMEN
The plant uptake of emerging organic contaminants such as pharmaceuticals and personal care products (PPCPs) is receiving increased attention. Biosolids from municipal wastewater treatment have been previously identified as a major source for PPCPs. Thus, plant uptake of PPCPs from biosolids applied soils needs to be understood. In the present study, the uptake of carbamazepine, diphenhydramine, and triclocarban by five vegetable crop plants was examined in a field experiment. At the time of harvest, three compounds were detected in all plants grown in biosolids-treated soils. Calculated root concentration factor (RCF) and shoot concentration factor (SCF) are the highest for carbamazepine followed by triclocarban and diphenhydramine. Positive correlation between RCF and root lipid content was observed for carbamazepine but not for diphenhydramine and triclocarban. The results demonstrate the ability of crop plants to accumulate PPCPs from contaminated soils. The plant uptake processes of PPCPs are likely affected by their physico-chemical properties, and their interaction with soil. The difference uptake behavior between plant species could not solely be attributed to the root lipid content.
Asunto(s)
Carbamazepina/metabolismo , Productos Agrícolas/metabolismo , Aguas del Alcantarillado/química , Contaminantes del Suelo/metabolismo , Aguas Residuales/química , Carbanilidas/metabolismo , Cosméticos/metabolismo , Difenhidramina/metabolismo , Preparaciones Farmacéuticas/metabolismo , Raíces de Plantas/metabolismoRESUMEN
The reactions between diphrenhydramine drug (diphen) in the base form and the iodine amphoteric reagent (n-donor and/or σ-acceptor) and tetracyanoethylene as a π-acceptor reagent (TCNE) have been spectrophotometrically studied at different conditions of reactant concentrations, time intervals, temperatures, solvents, and different wavelengths aiming to shed light on the nature of these reactions. Consequently, it is possible to select the proper conditions for spectrophotometric determination of this biologically active drug in its formulations. The reaction mechanism between iodine and diphen involves the formation of diphen-I2 outer-and inner-sphere complexes, whereas diphen-TCNE reaction involves the formation of charge transfer (CT) complex. The analytical parameters of the suggested spectrphometric procedures have been calculated. The values of the Sandell sensitivity, standard deviation (SD), relative standard deviation (RSD) and recovery % refer to the high sensitivity of these procedures applied in analysis of diphen in its formulations. This research also presents a new diphen-I2 promising drug derivative that can be used for the same purpose as its parent. Both diphen-drug and diphen-I2 separated solid product are critically investigated by elemental analyses, FT-IR, ¹HNMR, electron ionization mass spectrometry (EI-MS) and thermal analyses (TA). Practical investigation (TA and MS) data of diphen-drug and its reaction product are confirmed by MO calculations. This research gives a clear idea about the possible metabolites and metabolic pathways of diphen and its derivative in vitro system that may occur in vivo system. The importance of this drug stems from its use as an antihistamine with anticholinergic (drying) and sedative side effects.
Asunto(s)
Difenhidramina/química , Etilenos/química , Yodo/química , Nitrilos/química , Espectrometría de Masa por Ionización de Electrospray/métodos , Difenhidramina/metabolismo , Etilenos/metabolismo , Indicadores y Reactivos/química , Indicadores y Reactivos/metabolismo , Yodo/metabolismo , Nitrilos/metabolismo , Factores de TiempoRESUMEN
Many medicines available over the counter from pharmacies are known to have abuse potential, including diphenhydramine (DPH), an antihistamine with antimuscarinic properties used for the treatment of insomnia. We present a brief review of the literature describing DPH abuse, and report the case of GF, a 56 year old woman who was admitted to an inpatient addictions unit for detoxification from DPH. A literature search revealed five case reports of DPH abuse including a total of six patients, published between 1986 and 2001. All reported cases exhibited features of DSM-IV criteria for substance dependence, and there was an apparent link with antipsychotic usage. GF was treated with antipsychotics, and was using up to thirty 50 mg DPH tablets each day. She described feeling 'good and calm' and 'it stopped the tremors'. GF tolerated a gradual dose reduction schedule, and completed the detoxification programme relatively comfortably. She was discharged from the inpatient detoxification unit as planned, and had not relapsed at six months. The described case report highlights the importance of enquiring about non prescribed medication when taking a drug history. Similarly community pharmacists and GPs should be vigilant to excessive requests for DPH, particularly in patients with a psychotic illness.
Asunto(s)
Difenhidramina/metabolismo , Difenhidramina/toxicidad , Antagonistas de los Receptores Histamínicos/metabolismo , Antagonistas de los Receptores Histamínicos/toxicidad , Inactivación Metabólica/fisiología , Bases de Datos Bibliográficas , Manual Diagnóstico y Estadístico de los Trastornos Mentales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Medicamentos sin Prescripción/metabolismo , Medicamentos sin Prescripción/toxicidad , Centros de Tratamiento de Abuso de Sustancias , Factores de TiempoRESUMEN
Primary cultures of human hepatocytes are a reference cellular model, because they maintain key features of liver cells in vivo, such as expression of drug-metabolizing enzymes, response to enzyme inducers, and generation of hepatic metabolites. However, there is a restricted availability of primary hepatocytes, and they show phenotypic instability in culture. Thus, different alternatives have been developed to overcome the culture limitations and to mimic in vivo tissue material. Herein, culture conditions, such as medium composition, impeller type, and cell inoculum concentration, were optimized in stirred culture vessels and applied to a three-dimensional (3D) bioreactor system. Cultures of rat hepatocytes as 3D structures on bioreactor, better resembling in vivo cellular organization, were compared to traditional monolayer cultures. Liver-specific functions, such as albumin and urea secretion, phase I and phase II enzyme activities, and the capacity to metabolize diphenhydramine and troglitazone, were measured over time. Hepatocyte functions were preserved for longer time in the 3D bioreactor than in the monolayer system. Moreover, rat hepatocytes grown in 3D system maintained the ability to metabolize such compounds, as well as in vivo. Our results indicate that hepatocytes cultured as 3D structures are a qualified model system to study hepatocyte drug metabolism over a long period of time. Moreover, these cultures can be used as feeding systems to obtain cells for other tests in a short time.